Gyeonggi National Cancer Center
Gefitinib used as first-line therapy against advanced or metastatic lung cancer
Published in Lab Law Weekly, June 10th, 2005
"A subset of patients with adenocarcinoma of the lung who had never smoked cigarettes showed excellent tumor responses to gefitinib therapy. To evaluate the efficacy of gefitinib as a first-line therapy in this subgroup of patients, we conducted a phase II study," scientists in South Korea reported.
"Eligible patients had no smoking history, stage IIIB or IV adenocarcinoma, Eastern Cooperative Oncology Group performance status 0 to 2, and adequate organ functions. Treatment consisted of daily oral administration of 250 mg gefitinib for 28 days...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
Source: Lab Law Weekly (2005-06-10)
More Articles from Lab Law Weekly
- Ciphergen Biosystems, Inc.
ProteinChip System developer reports financial results for first-quarter 2005 - GenVault Corp.
Company gets rights to DNA labeling technology - Genitope Corp.
H. David Miller named VP of information technology and legal affairs - Heska Corporation
Diagnostics company announces 200th U.S. patent issued - Hollis-Eden Pharmaceuticals, Inc.
Pharmaceutical firm reports loss of $0.35 per share - LMA International NV
Designer of laryngeal mask files court action for patent infringement in Germany - More from this issue of Lab Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
